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PROFIL  FITOKIMIA, KESAN ANTI-ASMA DAN IMMUNOMODULASI  
DARIPADA Lignosus rhinocerus DALAM MODEL KERADANGAN SALUR 
PERNAFASAN  
 
ABSTRAK 
Lignosus rhinocerus (L. rhinocerus) atau lebih dikenali sebagai cendawan susu 
harimau, digunakan secara tradisional di kalangan masyarakat tempatan di Malaysia 
bagi merawat pelbagai penyakit termasuk asma. Walau bagaimanapun, 
keberkesanannya dalam rawatan asma dan potensi immunomodulasinya masih belum 
disahkan secara saintifik. Selain itu, maklumat tentang juzuk aktif cendawan ini juga 
jarang dilaporkan. Kajian ini mengkaji juzuk mudah meruap daripada ekstrak air 
panas (HWE), ekstrak air sejuk (CWE) dan L. rhinocerus mentah (CRD) dengan 
menggunakan kromatografi gas-jisim spektrometri (GC-MS). Kesan potensi ekstrak-
ekstrak L. rhinocerus terhadap aktiviti anti-asma telah disiasat pada tikus jantan 
Sprague Dawley yang telah dicetuskan keradangan pada saluran udaranya dengan 
menggunakan  ovalbumin (OVA).  Kesan immunomodulasi pula telah dikaji pada 
mencit BALB/c. Pengekstrakan berjujukan ke atas L. rhinocerus menggunakan lima 
pelarut (eter petroleum, eter, heksana, etil asetat dan metanol) telah dijalankan 
sebelum analisis GC-MS. Secara keseluruhan, 44 juzuk telah dikenal pasti daripada 
analisis CRD L. rhinocerus. Sebatian daripada kumpulan asid lemak adalah 
komponen yang paling utama (68.58%) manakala kompaun yang paling utama 
adalah asid linoleik (49.39%). Analisis GC-MS HWE pula mengenalpasti 18 juzuk 
dengan kompaun yang paling utama juga adalah asid linoleik (21.35%). Sebaliknya, 
GC-MS CWE hanya menunjukkan kehadiran metilsiklopentana (97.74%) dan 
sikloheksana (2.26%) sahaja. Untuk kajian asma, tikus jantan Sprague Dawley 
xvi 
 
disensitasi dengan 2 suntikan intraperitoneal 10 mg/ml OVA yang diemulsifikasi 
dalam 100 mg/ml aluminium hidroksida bersama-sama 50 ng/ml Bordetella pertussis 
pada hari 0 dan 14 diikuti  rawatan ektrak L. rhinocerus pada hari ke-21 selama 7 
hari. Dos yang optimum bagi L. rhinocerus HWE ialah 500 mg/kg, CWE ialah 250 
mg/kg dan CRD pula 250 mg/kg. Rawatan dengan ekstrak L. rhinocerus telah 
berjaya menambahbaik beberapa parameter yang berkaitan asma di dalam tikus yang 
diuji. Rawatan dengan HWE telah berjaya mengurangkan jumlah eosinofil dalam 
BALF, IgE dalam serum, sitokin Th2 (IL-4, IL-5 dan IL-13) dalam BALF dan 
infiltrasi eosinofil dalam paru-paru. Analisis sitometri aliran mendedahkan bahawa 
rawatan dengan HWE telah mengurangkan eosinofil dan meningkatkan sel T-
regulatori berbanding CRD dan CWE. Sebanyak 21 gen yang berkaitan penyakit 
asma telah berjaya di kawal atur selepas rawatan HWE. Kesan immunomodulasi 
ekstrak L. rhinocerus HWE telah dijalankan di dalam model in vitro dan in vivo. 
Mencit yang dirawat dengan ekstrak HWE L. rhinocerus menunjukkan penambahan 
populasi splenosit terutamanya populasi sel-sel CD3
+
 CD4
+
 dan CD3
+ 
CD8
+
 
berbanding kumpulan mencit yang tidak dirawat. Kajian ini juga menunjukkan 
proliferasi splenosit dan aktiviti fagositosis yang bertambah baik dan pengeluaran 
NO yang terkawal. Kajian ini menyimpulkan bahawa L. rhinocerus mempunyai 
potensi untuk digunakan sebagai alternatif bagi rawatan alergik asma. 
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PHYTOCHEMICAL PROFILES, ANTI-ASTHMATIC AND 
IMMUNOMODULATORY EFFECTS OF Lignosus rhinocerus IN AIRWAY 
INFLAMMATION MODEL  
 
ABSTRACT 
Lignosus rhinocerus (L. rhinocerus) or locally known as Tiger’s Milk mushroom, is 
traditionally used in the treatment of various diseases including asthma by 
indigenous communities in Malaysia. However, to date, its efficacy on asthma and its 
immunomodulating potential have not been confirmed by scientific studies.  Also, 
there is sparse information available on its active constituents. This study 
investigated volatile constituents of hot water extract (HWE), cold water extract 
(CWE) and crude (CRD) L. rhinocerus using gas chromatography mass spectrometry 
(GC-MS). The anti-asthmatic potential of L. rhinocerus extracts was investigated on 
ovalbumin (OVA)-induced airway inflammation Sprague Dawley rats. 
Immunomodulatory effects of L. rhinocerus were carried out in BALB/c mice.   
Sequential extractions of L. rhinocerus using five solvents (petroleum ether, diethyl 
ether, hexane, ethyl acetate and methanol) were conducted prior to GC-MS analysis. 
Overall, 44 constituents were identified from CRD L. rhinocerus. Compounds from 
the fatty acid group were the most predominant (68.58%) and the main constituent 
was linoleic acid (49.39%).  GC-MS analysis of HWE L. rhinocerus identified 18 
constituents with the main compound also linoleic acid (21.35%). In contrast, CWE 
only demonstrated the presence of methylcyclopentane (97.74%) and cyclohexane 
(2.26%). Male Sprague Dawley rats were sensitized with two intraperitoneal 
injections of 10 mg/ml OVA emulsified in 100 mg/ml aluminium hydroxide with the 
presence of 50 ng/ml of Bordetella pertussis, on days 0 and 14 followed by treatment 
xviii 
 
with L. rhinocerus extracts on day 21 for 7 days. Optimization study indicated 
optimized dosage for L. rhinocerus HWE was 500 mg/kg, CWE (250 mg/kg) and 
CRD (250 mg/kg). Treatments with L. rhinocerus extracts significantly ameliorated 
related asthmatic parameters in the induced rats. Specifically, HWE comparatively 
reduced eosinophils numbers in BALF, IgE in serum, Th2 cytokines (IL-4, IL-5 and 
IL-13) levels in BALF, and eosinophil infiltrations in the lungs than the CWE and 
CRD. Flow cytometry analysis revealed HWE to reduce eosinophils and improved T 
regulatory cells compared to CRD and CWE. A total of 21 asthma related genes were 
successfully down-regulated with HWE treatment. Immunomodulatory effects of 
HWE were studied in in vitro and in vivo model. Treatment with HWE L. rhinocerus 
extract demonstrated improved splenocyte population mainly of CD3
+
CD4
+
 and 
CD3
+
CD8
+ 
when compared with untreated mice groups. This study also 
demonstrated improved splenocytes proliferation and phagocytosis activity and 
controlled NO production. In conclusion, L. rhinocerus has the potential to be used 
as an alternative for the treatment of allergic asthma.  
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CHAPTER ONE 
INTRODUCTION 
1.1 Asthma 
The term ‘allergy’ was perceived by Von Pirquet in 1905 (Mekori, 1996). Allergic 
disorder is the consequence of an exaggerated reaction against innocuous 
environmental proteins or antigens. Some of the common allergic disorders include 
asthma, eczema, allergic rhinitis, anaphylaxis and autoimmune disorders (Porter et 
al., 2011). Despite continuous exposure to harmless antigens, some individuals 
experience adverse immunological responses to these antigens. This could be 
supported with the fact that normal immune response to allergens is linked with the 
initiation of tolerance. Thus, retraction of tolerance leading to further tolerance may 
cause induction and prolongation of active immune responses (Romagnani, 2000). 
There are four types of allergic responses based on the mechanism of immunological 
involvement which are known as Types I to IV allergic reactions. Immediate 
hypersensitivity reaction is the Type I allergic reaction where major components 
involve allergen, immunoglobulin (Ig) E antibody, mast cell and their mediators in 
which asthma is a known example (Tortora and Derrickson, 2008). 
 
Asthma is a disease affecting 300 million lives globally and is a result of  complex 
interplay between genetic and environmental factors (WHO, 2013). It is a disease  
characterized by persistent wheezing, shortness of breath, chest tightness 
and coughing (Konno et al., 2002).  The airway disorder is commonly characterized 
by airway eosinophil infiltration, airway hyperresponsiveness (AHR), excessive 
airway mucus production and increased serum IgE and T-helper 2 cytokine levels 
including interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13) 
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(Wardlaw et al., 1988; Lukacs, 2001; Elias et al., 2003). Generally asthma is 
mediated by an over exuberant response of Th2 inflammatory responses, leading to 
exaggerated airway eosinophilia infiltration and lung mucus production (Issekutz and 
Sapru, 2008). 
 
1.1.1 History  
Ancient ways of treatment and drugs used against asthma have been documented for 
as long as 5000 years ago (Huntley and Ernst, 2000). Various countries have 
contributed to this knowledge including Ancient China, Egypt, Greece, Rome and 
India. It is apparent that their medicinal approach, specifically for asthma, was 
closely interwoven with religious and cultural practices. One of the earliest document 
called ‘Su Wen’ from China, reported on how asthma is interpreted by seasonal 
aspect of the respiratory disease (Cserhati, 2004). This writing is dated by scholars 
between 475 and 221 BC (Veith, 2002). It explains that the disease when located on 
lung region is improved during winter season and it will escalate and worsened by 
summer. It has also been reported that if the disease withstand and continued without 
any mortalities, the conditions can be warded off during summer evening although 
the disease can exarcebate again during autumn. Such common environmental 
factors of asthma is also reported in other regions in the world (Cserhati, 2004).  
 
In Greece, Hippocrates the Great, also known as ‘father of medicine’ (460-377 BC) 
was one of the first to establish the relationship between the environment and 
respiratory ailments (Chadwick, 1950). The original term of asthma came from the 
verb “azein” which in Greek means exhalation with an open mouth and to pant 
(Marketos and Ballas, 1982). The term was continued among Greek physicians in 
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describing the degree of respiratory defects. On another account, asthma also means 
for ‘wind’ or ‘to blow’ in Greek (Cserhati, 2004).  
 
In Chinese culture, the ancient healers named asthma as ‘xiao-chiran’ which means 
wheezy breathing as a result of imbalance in the life force, “Qi”. Therefore, the 
imbalance life “Qi” has to be restored by means of herbs, acupuncture, massage, diet 
and exercises (Lao et al., 2012). Meanwhile, Indian medicinal practitioners related 
breathing difficulties to human’s soul in connection to the mind, body and spirit in 
which yoga was often the most applied method of meditation along with breathing 
techniques (Singh, 2006).  
 
1.1.2  Prevalence of asthma 
It is estimated that 250,000 people die every year due to asthma (Bateman et al., 
2008; WHO, 2013). According to the World Health Organization (WHO), the 
number of asthma patients are increasing and is expected to reach to 400 million by 
2025 (Pawankar, 2014). The disability-adjusted life years (DALYs) lost rate due to 
asthma worldwide is estimated to be 15 million per year which is comparable with 
diabetes, liver cirrhosis and schizophrenia (Bousquet et al., 2005). In addition, 
asthma has been estimated to account for at least one death for every 250 mortality 
worldwide (Masoli et al., 2004). Poor management and uncontrolled asthmatic 
condition often affected the quality of life and daily activities of the sufferers 
(Haselkorn et al., 2010). In some cases, it causes depression and subsequently leads 
to increased hospital visits (Sullivan et al., 2007). 
 
In Asia, asthma mortality rates in more affluent areas such as Hong Kong and Japan, 
are similar to those reported in Western countries (Lai et al., 1996). The severity of 
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asthma and control measures are important in evaluating patients and their response 
towards treatment not only in public health registries but also in research (clinical 
trials, epidemiologic, genetic and mechanistic studies) (Bousquet et al., 2010). 
Therefore, the Global Initiative for Asthma (GINA) was developed by WHO in 
collaboration with the US National Heart, Lung, and Blood Institute to establish a 
more generally accepted diagnostic and management strategies in its proper 
diagnosis.  
 
1.1.3 Asthma in Malaysia 
In Malaysia, approximately 80% to 90% of asthmatic children and young adults were 
found to have allergy asthma (Gendeh et al., 2004). The International Study of 
Asthma and Allergies in Childhood (ISAAC III) has estimated that the prevalence of 
asthma in Malaysia has increased from 6.4% to 9.4% in children from between 6 and 
7 years of age to 9% to 13% among children between 13 and 14 years (Pearce et al., 
2007; Yadav et al., 2014). Allergic asthma is common among children and often 
related to genetic inheritance. On the other hand, non-allergic asthma (20%) is 
commonly found in middle-aged and the elderly. Statistical studies conducted among 
Malaysians reported that children with asthma showed various responses to specific 
allergens. Approximately 90% of patients are allergic to house-dust mites, 67% to 
cockroach, 23% to cat dander or dog epithelium and 10% to 22% to foods including 
cow’s milk, soya bean, egg, peanut, fish, shrimp, crab, banana, and wheat (Gendeh et 
al., 2004).  
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1.1.4 Aetiology 
The development of asthma involves both exogenous and endogenous factors as 
evidenced by its onset at the beginning of infancy or childhood (Dietert, 2011). 
Combination of genetic predisposition with environmental factors affect its severity 
and responses to treatment (Choudhry et al., 2007). Factors that further provoke the 
allergic reactions or irritate the airways includes indoor allergens including 
cockroaches, mold, house dust mites in bedding, carpets and pet dander (Arshad, 
2010; Kelly and Fussell, 2011). Surprisingly, indoor volatile organic compound such 
as formaldehyde is also a known trigger (McGwin Jr et al., 2010). 
Phthalates in PVC has been also associated with asthma in children as well as adults 
(Bornehag and Nanberg, 2010). Meanwhile, perfumes are common cause of acute 
attacks in women and children (Lessenger, 2001). Chemical irritants in the 
workplace, air pollution, other environmental chemicals and low air quality caused 
by traffic pollution or high ozone levels has been widely reported as causes of 
asthma (Kroegel, 2009). Smoking during and after pregnancy  delivery is highly 
associated with a greater risk of asthma (Bousquet et al., 2007). Moreover, 
psychological stress is also believed to worsen the symptoms, where it alters immune 
system thus increases the airway inflammatory response to allergens and irritants 
(Gold and Wright, 2005).  
 
Some viral respiratory infections, such as respiratory syncytial virus and rhinovirus, 
cause high risk of asthma when acquired as young children (Murray John and Nadal 
Jan, 2000) and infections of upper respiratory tract can further worsen the asthmatic 
condition (Baxi and Phipatanakul, 2010). Nutritional aspect also plays a major role in 
the development of allergic disease. Deficiency of vitamins, fatty acids, antioxidants 
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sources as well as imbalance of the gut micro flora causes interference of this 
homeostasis and leads to development of allergy (Holgate and Polosa, 2008). Family 
history is also one of the contributing factor for asthma development (Burke et al., 
2003).  
 
1.1.5 Types of asthma 
Asthma can be divided into several types, namely allergic, non-allergic, exercise 
induced, nocturnal, occupational and steroid resistant asthma (Paliwal, 2012). 
Allergic asthma is highly related to family history of allergic diseases such as eczema 
and allergic rhinitis (Bel, 2004; Moore et al., 2010; Wenzel, 2012).  Non-allergic 
asthma (intrinsic) on the other hand, occurs when there is no allergy involved 
(Paliwal, 2012). Many non-allergic asthma populations experience exercise-induced 
asthma. In nocturnal asthma, patients experience asthma when they are sleeping 
(Yawn, 2008). Long periods of direct exposure to chemical fumes, wood dust or 
other irritants leads to occupational asthma. Lastly, steroid-resistant asthma is caused 
by steroid overdose which leads to severe asthmatic attack that may not respond to 
medication and may require ventilation (Paliwal, 2012). Other common phenotypes 
identified include late-onset asthma which occurs particularly among women for the 
first time in adult life and asthma with fixed airflow limitation which is caused by 
airway wall remodelling. Asthma also occurs in an obese where such patient may 
have noticeable respiratory symptoms with slight eosinophilic airway inflammation 
(Bel, 2004; Moore et al., 2010; Wenzel, 2012).  Previously the WHO also proposed a 
uniform definition of severe asthma in 2009. Finally, following a review by the 
Global Alliance against Chronic Respiratory Disease, severe asthma is classified into 
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three groups; (1) untreated severe asthma, (2) difficult-to-treat severe asthma and (3) 
treatment-resistant severe asthma (Bousquet et al., 2010).  
 
1.1.6  Immunopathogenesis  
Asthma and other allergic related mechanisms are known to be a T helper 2 (Th2) 
dominated response. The response is initially triggered when an airway allergen is 
taken by antigen presenting cells and presented to specific Th cells by means of 
major histocompatibility complex (MHC) class II followed by initiation of the 
immunological synapse (Valenta et al., 2003). This activated allergen-specific T 
helper cells then polarize into Th1 or Th2 effector populations, followed by 
differentiation into a Th2 subpopulation. These activated Th2 cells then engage in 
recruiting and activating cytokines such as interleukin (IL)-4, IL-5 and IL-13 
followed by stimulation of eosinophil. At the same time, B lymphocytes produce 
antigen-specific IgE that binds to its high-affinity receptor on the mast cells to enable 
mast cell degranulation by crosslinking (Amin, 2012) leading to IgE release and 
binding to IgE receptors on mast cells, basophils, and eosinophils (Maes et al., 
2014). Upon allergen crosslinking with mast cell-bound IgE, a large number of 
preformed and newly synthesized mediators are released, including histamine, 
cysteinyl leukotrienes and proteases (Figure 1.1) (Holgate and Polosa, 2008). 
Generally, the immediate release of histamine and leukotrienes occurs before the 
prostaglandins release, followed by the production of cytokines after a few hours 
(Maes et al., 2014). In an allergic individual, the IgE-sensitized mast cells 
degranulates in a very short period of making contact with the allergen as an early 
allergic reaction (Holgate and Polosa, 2008). The mediators released basically causes 
vascular permeability, bronchoconstriction and excessive mucus production which  
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Figure 1.1:  Initiation of immunological cascade after allergen exposure. Allergen is 
taken by APC and presented to specific Th2 cells by means of major 
histocompatibility complex (MHC) class II. The activated IL-4 and IL-13 stimulates 
B-cell for IgE, while IL-15 regulates eosinophils recruitments. Upon repeated 
exposure, allergen crosslinking with mast cell-bound IgE and leads to mediators 
release by degranulation thereby further exacerbating the allergic inflammatory 
responses. Adapted from (Singh and Bhalla, 2008). Abbreviations: APC, antigen 
presenting cells; Th2, T-helper 2; IL-, interleukin-, IgE, immunoglobulin E. 
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subsequently intensify the allergic manifestations (Holgate and Polosa, 2008; Amin, 
2012).  The roles of prostaglandin E2 (PGE2) and nitric oxide (NO) have been 
highlighted as their upregulation has been identified to allow enabling histamine to 
modulate the cytokine networks upon allergic reactions (Packard and Khan, 2003).  
 
Recently, the involvement of regulatory T (Treg) cells which is another important 
subset of CD4+ T cells have been highlighted for its protective role in suppressing 
Th2 cell responses in allergic inflammations (McAlees et al., 2015). Their 
mechanisms are specifically associated with the neutrophilic inflammatory events 
that follows disease exacerbation and tissue remodelling (Holgate and Polosa, 2008). 
In addition, they also directly inhibit the proliferation of effector T cells or through 
antigen-presenting cells (Workman et al., 2009). Th2-mediated airway inflammation 
in asthma may also result from the suppression of Tregs (Boulet et al., 2012), which 
is being studied for potential therapeutic focus in treating asthma (Jin et al., 2013).  
Development of asthma is unclear and may lead to worse condition if left untreated. 
An exacerbated hyper reaction and symptoms of allergy may affect the respiratory, 
gastrointestinal, nervous and even cardiovascular systems. In addition, severe 
complex condition of allergy, namely anaphylaxis, can also occur resulting in an 
anaphylactic shock with hypotension and finally leading to death (Abril-Gil et al., 
2012).  
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Currently, many studies mainly focus on various parameters such as neutrophils, 
eosinophils, immuglobulin and interleukins on the levels of which are variable in 
asthmatic patients. Although various studies reported that neutrophil is associated 
with acute bronchial hyperresponsiveness and is claimed to be active participant in 
epithelial damage, the presence of several neutrophils in epithelium is noted to be a 
normal phenomenon, since they are also reported to be present in the bronchial 
lavage fluid (BALF) of normal subjects (Kaliner et al., 1990). In addition, 
eosinophils serve as an important marker during the development and expression of 
allergic inflammation. These multifunctional granulocytes are produced and derived 
in the bone marrow from myeloid progenitors (Stevens et al., 2007). Eosinophils 
secrete various proteins including eosinophil cationic protein, peroxidase and 
histamines (MacKenzie et al., 2001; Humbles et al., 2004). During an exaggerated 
asthma reaction, eosinophils accumulate in the respiratory tracts and infiltrate the 
lung regions (Stevens et al., 2007) which allows their quantitation as a standard 
measurement in inflammation on murine allergic airway sensitization models, 
including those exposed to chicken egg albumin administration for sensitization 
(Varga et al., 2000; Varga et al., 2001).  
 
Since IgE is involved in allergy development it is also associated with asthma. 
Generally, IgE has a very short life and is present in low amount compared to other 
immunoglobulin (Oettgen and Geha, 1999). However, the low concentration of IgE 
in the circulation does not reveal its true allergic activity and therefore, they are 
highly sensitive to allergens despite being present in low concentration in the 
circulation (Platts-Mills, 2001).  
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Cytokines such as interleukin plays important roles as mediators amid leukocytes and 
mediates inflammation in asthmatic patients. Increased expression of Th2 cytokines 
(IL-4, IL-5 and IL-13) has been reported in the BALF of asthmatic patients. It has 
been highlighted that the imbalance between Th1 [interferon gamma (IFN-γ) and IL-
2] and Th2 (IL-4, IL-5,and IL-13) cytokines is an important mechanism that leads to 
asthma (Busse and Lemanske, 2001). IL-4 has been hypothesized for its key role in 
the pathogenesis of asthma. It has a crucial role in causing class switching of Ig 
isotype B cells, resulting in IgE synthesis (together with IL-13) which is involved in 
mast cell degranulation by crosslinking with IgE receptors (Bateman et al., 2008; 
Lee et al., 2010). Generally, asthmatic individuals have elevated IL-4 protein levels 
in BALF and serum as well as increased IL-4 mRNA and protein in bronchial 
biopsies (Humbert et al., 1996; Kotsimbos et al., 1996). It has been reported that 
aerosol nebulization of IL-4 in individuals who are mildly asthmatic prompts airway 
hyper responsiveness (AHR) and eosinophilia (Shi et al., 1998). Various strategies 
therefore target IL-4 as potential therapies. For instance, a study on IL-4–deficient 
mice indicated a reduced eosinophilic inflammation and peribronchial inflammation. 
It was also reported that the IL-4–deficient mice neither produced total and allergen-
specific IgE nor expressed the development of AHR (Brusselle et al., 1994). 
Molecular signalling of IL-4 via IL-4Ra activates the transcription factor Stat6, 
causing up-regulation of Th2 lineage–specific transcription factor GATA-binding 
protein 3(GATA-3) expression. Nonetheless, IL-4 dominates by directing Th2 cell 
polarization (Maes et al., 2014). 
 
IL-5 enhances eosinophil recruitment, activation and survival at the inflammatory 
sites (Fujisawa et al., 2000; Farahi et al., 2007). It also modulates the eosinophil 
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progenitors in asthmatic individuals (Menzies‐Gow et al., 2007) and influences  the 
growth and differentiation of bone marrow eosinophils (Sanderson, 1987; 
Yamaguchi et al., 1988). Studies on allergen-induced inflammatory responses and 
AHR using anti-IL-5 revealed that the IL-5 knockout mice are protected from AHR 
(Foster et al., 2002), acute allergic inflammation and chronic airway remodeling 
(Cho et al., 2004). However, focusing on single interleukin alone as therapeutic 
target has not been very successful. For instance, IL-5 antagonists has been 
ineffective in clinical studies (Kips et al., 2003; Nials and Uddin, 2008).  
 
On the other hand, IL-13 known as ‘‘central mediator of allergic asthma’’ plays an 
important role in allergic response in asthmatic patients (Bateman et al., 2008). IL-13 
is involved in class switching of B cells to produce IgE, that regulates eosinophilic 
inflammation, airway smooth-muscle hyperplasia and the recruitment of monocytes, 
as well as macrophages and T cells in airway (Wynn, 2003; Holgate and Polosa, 
2008). In fact, it has been shown that IL-13 alone is sufficient to induce responses in 
murine models (Ingram and Kraft, 2012). In a study using allergen sensitized mice, 
the selective blockade of IL-13 was achieved by using a soluble form of IL-13Rα2 
that competes with IL-13 binding leading to airway hyper responsiveness and 
reversal of mucus production (Grünig et al., 1998). Nevertheless, IL-13 is mainly 
involved in inducing goblet cell hyperplasia, airway remodeling mucus 
hypersecretion and AHR (Wills-Karp et al., 1998). 
 
Since asthma pathogenesis is extremely complex, efforts to exclusively target on 
Th2-type cells alone had little effect and failed to progress to clinical trials (Leckie et 
al., 2000). Moreover, the balance between Th1 and Th2 cells are claimed to be 
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inadequate to elicit many experimental observations (Wills-Karp et al., 2001; 
Herrick and Bottomly, 2003). Often, Th1 cells itself contribute to exacerbations and 
disease manifestations of asthma in mouse models (Hessel et al., 1997; Hansen et al., 
1999; Ford et al., 2001). The roles of Treg cells in asthma are gaining great research 
interest (van Oosterhout and Bloksma, 2005; Li et al., 2012). The immunoregulatory 
effects of Tregs is becoming more important as it is purported to be involved in 
suppressing conventional CD4 T cells-mediated immune responses. 
 
Recent candidates of Tregs being widely investigated are Th3 (T helper 3), TR1 
(Type 1 regulatory T cells), CD4+, CD25+ and natural killer (NK) T cells. TR1 cells 
can prevent experimental colitis and Th2 responses (Tsitoura et al., 2000). TR cells 
have also been shown to inhibit AHR. Naturally occurring regulatory CD25+ cells 
are involved in preventing autoimmune disease (Umetsu et al.2003). For example, a 
study conducted on asthmatic children reported significantly decreased levels of 
CD4+CD25hi Tregs and Foxp3 mRNA expression, highlighting a decrease of these 
Treg cells influences Th2 balance (Hartl et al., 2007). Nonetheless, exact roles of 
Tregs cells in controlling the development of asthma are still unclear. Nevertheless, 
TR1 cells plays roles in inhibiting Th2 and Th1 responses (Cottrez et al., 2000) and 
regulate the growth of Th2 responses and AHR (Akbari et al., 2002). CD25+ cells is 
speculated to inhibit the development of airway eosinophilia (Suto et al., 2001) but 
not AHR (Hadeiba and Locksley, 2003).  
 
1.1.7  Pathophysiology and clinical features 
The presence of respiratory epithelial cells in the sputum was one of the first 
pathological abnormalities as described by Curschman in 1885. Thus, many 
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approaches focused on sputum for studies on patients suspected of suffering from 
asthma or airway inflammation. Many indirect approaches on examination of airway 
structure, such as airway inflammation and airway hyperresponsiveness have been 
performed although difficulties lies in obtaining the representative specimens of 
humans airways (Melder, 2005). The Beta Adrenergic Theory of Asthma in 1968 led 
to one of the most important watershed moment in research related to allergic.  The 
theory brought an understanding of asthma pathogenicity where a study has reported 
that the blockage of beta-2 receptors of pulmonary smooth muscle cells lead to 
asthma (Szentivanyi, 1968).  Later, it was demonstrated that over production of IgE 
causes blocking of beta-2 receptors, thereby making clear the central role of IgE in 
allergic diseases (Szentivanyi et al., 1993).  
 
The hallmark of asthma is the functional changes that is associated with airways 
obstruction (Dunnill, 1960) In asthma, the "hypersensitive" inflamed airways 
respond to the presence of environmental allergens or triggers, causing airways 
narrowing and increase production of mucus, leading to difficulty in breathing. In an 
asthmatic patient, the walls of the airways in the lungs are irritated and swollen as the 
muscles surrounding airways becomes more sensitive and they form a more 
spontaneously tightened and compressed muscles (Cockcroft, 1983; Fahy and 
Dickey, 2010). Hence, contraction of smooth muscle of bronchi (large airways) leads 
to spasm, resulting in an asthmatic attack. Other airway remodelling and structural 
changes include subepithelial fibrosis, enlarged smooth muscle mass, glands and 
thickening of airway walls as well as bronchial hyper responsiveness. This is also 
followed by airway oedema and excessive mucous hypersecretion (Bergeron et al., 
2009). Other known airway remodelling characteristics are angiogenesis, loss of 
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cartilage integrity and inflammation (Bergeron et al., 2010). Further contraction 
follows after inflammation of the airways and mucus production leading to coughing 
and breathing difficulties (Figure 1.2). On the other hand, AHR is an occurrence in 
the presence of excessive airway narrowing upon sensitive chemical or physical 
stimuli that exert little or no harm to a normal individual (Brusasco and Pellegrino, 
2013). A study on the relationship between inflammation and AHR reported that 
alteration on inflammatory signalling pathways on mouse and its effects of 
sensitization which revealed that inflammation and AHR do not directly correlate. 
Thus, it was proposed that a more mechanistic investigation may examine clearly the 
potential causal impact of inflammation on AHR (Janssen-Heininger et al., 2012).  
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Figure 1.2: Airways  narrowing and the release of excess mucus, causing breathing 
difficulties . Adapted from Doeing and Solway (2013).    
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1.2 Drugs and treatment 
1.2.1 Current drugs and therapies 
Various drugs were used decades ago, such as adrenaline and isoproterenol in 
treating asthma. However, over the years, side effects of these adrenergic agonists 
lead to the production of newer drugs with major advantages over the former. For 
instance, the newer drugs such as metaproterenol, terbutaline and salbutamol 
expressed better and longer duration of action while acting selectively as pure beta2 
stimulators, thus alleviating undesirable cardiovascular stimulation (Goldberg, 1976). 
Currently, pharmacological agents such as inhaled corticosteroids, anti-histamines 
and β2-adrenoceptor agonists such as short- and long-acting β2-adrenoceptor 
agonists (SABAs and LABAs) are the mainstay of asthma treatment as supported by 
asthma management guidelines. These drugs are aimed to treat different allergic 
symptoms (Holgate and Polosa, 2008; Abril-Gil et al., 2012).  To date, inhaled 
corticosteroids and leukotriene inhibitors such as beclomethasone, budesonide and 
dexamethasone have long been used for the management of asthma for more than 50 
years. They have been efficiently reducing the severity of symptoms and improving 
the lung functions while β-adrenergic agonists (salbutamol, terbutaline and fenoterol) 
and anticholinergics (Brown et al., 1992; Mali and Dhake, 2011) have been used for 
maintenance therapy.  These drugs help to relieve asthmatic symptoms  and attacks 
by relaxing the airway of smooth muscle (Kim and Yang, 2011). In most cases, the 
combination of drug that relieves and control the symptoms present as the foundation 
of disease management (Holgate and Polosa, 2008).  
 
Meanwhile, new approach as anti-IgE drug known as omalizumab, has been used to 
control asthma severity. Omalizumab was the first biological agent used for allergy 
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treatment and paved the way for more studies on such potential biological agent to 
target cells and receptors. It is a humanized IgE-specific and non-anaphylactic IgG1 
drug which has been developed and confirmed in clinical trials to control the disease 
symptom in patients when combined with lower doses of inhaled corticosteroids 
(Holgate et al., 2005). Reducing circulating IgE levels has been the target for asthma 
treatment, as also seen with lumiliximab, an antibody specific to the low-affinity IgE 
receptor (Poole et al., 2005). Otherwise, methods such as vaccine and allergen-based 
therapies are also some of the important strategies in allergy prevention and 
treatment, specifically with the involvement of recombinant allergens and peptide 
fragments. The coupling of allergens with oligonucleotide stimulatory sequences also 
transformed the whole conceptual prospect of asthma treatment (Holgate and Polosa, 
2008).   
 
1.2.2 Side effects and limitation of drugs  
Despite their efficiencies in treating asthma, current medications for asthma which 
are mainly steroid-based have some side-effects and limitations. For example, 
synthetic drugs such as salbutamol, terbutaline and fenoterol only prevent early 
stages of asthma attacks. They cannot be used for chronic persistent asthma attacks, 
which need steroids inhalation. Steroids are anti-inflammatory drugs that affect and 
act directly on the lungs to provide a long-term relief. The side effects of 
corticosteroid is however apparent. Inhaled corticosteroid is expected to be more 
effective in reducing symptom compared to the orally consumed corticosteroid. 
However, drugs such as beclomethasone dipropionate (BDP) and budesonide are 
claimed to have weak active metabolites following liver biotransformation in the 
liver. In contrast to BDP and budesonide, dexamethasone is more effective when 
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taken orally rather than via the inhalation mode (Mali and Dhake, 2011). Inhaled 
corticosteroid also has negative side effects as they are absorbed into the systemic 
circulation and may lead to undesired effects such as impaired growth, decreased 
bone mineral density and cataracts and many more (Dahl, 2006; Kaliner et al., 1990). 
Since anticholinergic, nevertheless are reported to be less effective when compared 
to β-adrenergic agonists, they may be used together for additional results or effects 
(Mali and Dhake, 2011). However, physicians are still uncertain in long-acting beta2 
agonist drugs role for asthma which cannot be used alone due to severe side effects. 
Therefore, Food and Drugs Association (FDA) recommends using these products 
together with steroids (Chowdhury and Dal Pan, 2010). 
  
In fact, many complications from synthetic drug have been reported such as 
detrimental effects on calcium metabolism leading to osteoporosis following long 
term medications. Other local and systemic side effects are oral candidiasis, 
dysphonia, growth failure, elevated intraocular pressure and mild tachyphylaxis 
(Fanta, 2009). In addition, resistances towards drugs and treatments were also 
increasing despite more efficient response in treating and relieving symptoms 
(Kaliner et al., 1990). Basically, with the application of current drugs, the occurrence 
of recurrent attacks and asthma exacerbations still occur. A new drug called 
Altrakincept which involves targeting of IL-4 for the treatment of asthma has failed 
phase III trial due to some bioavailability issues (Holgate and Polosa, 2008). 
 
Currently, the majority of available drugs are only effective in preventing early 
stages of asthma and are unable to provide immediate symptomatic relief especially 
for acute attacks. Due to the inadequacy of modern medicine, natural products and 
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nutritional interventions are frequently utilized to aid in the prevention, diagnosis and 
management of asthma (Lee et al., 2007; Lee et al., 2010; Abril-Gil et al., 2012). 
The Th2 cells driven inflammatory responses has been known to lead to 
enhancement of airway eosinophilia and lung mucus production. Various researches 
are therefore primarily focused on products which have the potential to reduce IgE, 
IL-4, IL-5, IL-13 and eosinophils as therapeutic targets in the context of identifying 
anti-asthmatic properties (Lee et al., 2007; Lee et al., 2010; Zhang et al., 2011; 
Abril-Gil et al., 2012).  
 
1.2.3 Complementary and alternative medicine in asthma 
The complementary and alternative medicine (CAM) is becoming more popular now 
among the public due to the enormous increase in access to worldwide information 
through the World Wide Web and widespread news and media coverage. Generally, 
CAM can be categorized into whole medical systems, natural products, manipulative 
and body-based practices, movement therapies, traditional and energy field healing 
(George and Topaz, 2013). Natural products have been widely benefited since 
centuries ago, although the necessity of its scientific evident on its efficacy was 
overlooked. The preference towards such herbal alternative is surprisingly high in the 
modern era. Interestingly, patients are also aware that such interventions are not 
wholly curative. Instead they function more towards symptom relieving and 
improving the quality of life. A study in the United States reported that 55% of adults 
prefer to use herbal remedies along with conventional medicines, while 28% of 
adults solely rely on natural products due to the assumption that synthetic drugs are 
more toxic while others feel that synthetic drugs are also expensive (Mahmoudi, 
2009). Nevertheless, there is limited evidence supporting the value of CAM 
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treatments from many clinical trials. Many studies have described its use among 
patients (Blanc et al., 2001; Berg et al., 2015; Ward and Baptist, 2016) and reported 
their effectiveness for allergic-related diseases (Lakshmana et al., 2001; Zhang et al., 
2011; Abril-Gil et al., 2012).   
 
Promising Anti-asthma Herbal Medicine Intervention (ASHMI) is run along with 
plant-based medicines in some clinical studies of asthma. ASHMI is a combination 
of three herbs known as Ganoderma lucidum mushroom, Radix Sophora flavescentis 
and Radix Glycyrrhiza uralensis (Gan Cao) (Wen et al., 2005). ASHMI confirms 
therapeutic effects on major pathogenic mechanisms of asthma including AHR, 
airway inflammation and remodelling as well as alleviation of Th2 immune reaction. 
The direct inhibitory role on airway smooth muscle was also reported (Srivastava et 
al., 2005; Li and Brown, 2009). In addition, a preclinical trial of Gan Cao confirmed 
to its anti-inflammatory properties and potential control over ‘neutrophilic asthma’. 
The intervention decreased the levels of mediators such as IL-8, eotaxin 1 and Signal 
transducer and activator of transcription6 (STAT6) in human lung fibroblast cell line 
(Matsui et al., 2006; Nair et al., 2015). The clinical trial was conducted after the 
novel herbal formula found to show effective therapy in a murine model of allergic 
asthma. The clinical success was observed with apparently a harmless and effective 
alternative medicine for treating asthma. In contrast with prednisone, of oral ASHMI 
capsules had no adverse effects on the adrenal function (Wen et al., 2005).  
 
1.2.4  Development of natural-based medication for asthma 
Many studies reported on the effectiveness of various natural products on asthmatic 
animal models. Viola mandshurica (VM), a Korean traditional herbal medicine has 
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been reported to show anti-asthmatic effects in an animal model (Lee et al., 2010). 
Another study also showed the efficacy of Elaeagnus pungens in anti-asthmatic 
formulations (Ge et al., 2009). Similarly, Rhus succedanea (Japanese wax tree), 
Solanum xanthocarpum (yellow-fruit nightshade), Tylophora indica (vine plant), 
Albizzia lebbeck (flea tree), Glycyrrhiza glabra (licorice) and Achyranthes aspera 
(prickly chaff flower) have been reported to cause mast cell stabilization, have anti-
histamine, anti-cholinergic, anti-anaphylactic actions and is effective against allergic 
asthma disorders (Lakshmana et al., 2001; Gopumadhavan et al., 2005). Other 
therapeutic relieve of bronchoalveolar inflammation in airway of the sensitized 
murine model have also been shown by Ganoderma tsugae mushroom extract (Lin et 
al., 2006). Similarly, the extract from the medicinal Basidiomycetes mushroom also 
demonstrated anti-allergic and anti-inflammatory effects (Hetland et al., 2015). 
Another herb, Cordyceps sphecocephala, known for its traditional use in Korea, 
China and Japan was widely used to treat cancer and hypocholesterolaemia has also 
been reported to alleviate the expression of IL-4, IL-13 and IL-25 in allergic murine 
model (Heo et al., 2010) highlighting their potentials.  
 
1.3 Mushroom and its potential immune response 
Mushroom is one of the most consumed medicinal plants due to of their nutritive 
values and low calories (Agrahar-Murugkar and Subbulakshmi, 2005), essential fatty 
acids (Manzi et al., 2001) vitamin and minerals (Manzi et al., 2001). In addition, it 
has anti-bacterial and anti-viral properties (Breene, 1990). Various types of 
mushrooms are also traditionally used for their effects against cancer, asthma and 
inflammatory responses (Rowan et al., 2003). Mushrooms are also well known for 
their abundant polysaccharides chitin and beta-glucan compositions that have 
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prominent roles in modulating airway inflammation. Previous studies have shown 
that chitin can inhibit the development of the quintessential features of asthmatic 
disease including chronic airway inflammation, AHR and pathological remodelling 
changes in mouse models of allergy (Catalli and Kulka, 2010). Notably, the boiled 
extract of Lignosus rhinocerus sclerotium has been widely used to treat cough and 
asthma traditionally (Chang and Lee, 2004). The active compounds, β-glucan is 
confirmed in many studies to be the key essence in asthma-healing (Catalli and 
Kulka, 2010), yet L. rhinocerus’s potential in asthma still remains unclear.  
 
The immunomodulating effect of mushroom has gained some interest (Mau et al., 
2001; Rowan et al., 2003) where it is explored in many studies (Rowan et al., 2003; 
Lindequist et al., 2005; Nurul et al., 2014). Pleurotus sajor caju (PSC) an edible 
mushroom commonly found in the tropical region has shown immunomodulatory 
effects in BALB/c mice (Nurul et al., 2014). Similarly, the immunomodulatory 
effects of Polyporus rhinocerus mushroom from China has also been reported (Wong 
et al., 2011) where it improves the general immune status such as balancing T helper 
cells and T cytotoxic cells, increase B cell as well as macrophages populations 
(Nurul et al., 2014). 
 
1.4 Lignosus rhinocerus “Tiger’s milk mushroom” 
Lignosus rhinocerus of Polyporaceae family is one of the exclusive wild mushrooms 
found in Malaysia. It is locally known as “cendawan susu rimau” or “tiger’s milk 
mushroom”. This unique mushroom is one of the total 38 types of edible mushrooms 
in Malaysia which is used for its medicinal purposes by the rural and indigenous 
communities (Lee et al., 2009). The name “tiger milk mushroom” was originated 
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from the belief that it vegetates from the ground where the tigress leaked its milk 
while feeding her cubs. The structures of L. rhinocerus comprise of pileus, stipe and 
sclerotium (Figure 1.3). It is believed that the tuber or sclerotium of L. rhinocerus 
can remain in the ground for periods ranging from several months to decades, and the 
mushroom will only grow solitarily when the nature calls. The underground tuber is 
the most treasured portion of L. rhinocerus due to its medicinal value (Lee et al., 
2011b). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
